Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 2/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16516503 | 1.00 | PTGER3 (0.53) | PTGER3PTGDRPARP10NPC1RAB9A | |
| SCHEMBL30106325 | 0.85 | PARP10 (0.48) | PARP10NPC1RAB9AFFAR1AKR1B1 | |
| SCHEMBL16516225 | 0.81 | ALDH1A1 (0.64) | PTGER3PTGDRKDM4EALDH1A1PKM | |
| SCHEMBL16516226 | 0.81 | ALDH1A1 (0.64) | PTGER3PTGDRKDM4EALDH1A1PKM | |
| SCHEMBL15249111 | 0.76 | NPC1 (0.63) | PARP10NPC1RAB9AFFAR1AKR1B1 | |
| SCHEMBL16516663 | 0.75 | PARP10 (0.60) | PARP10NPC1RAB9APARP15MEN1 | |
| SCHEMBL15249114 | 0.74 | MEN1 (0.56) | PARP10NPC1RAB9AFFAR1AKR1B1 | |
| SCHEMBL15249123 | 0.73 | NPC1 (0.64) | PARP10NPC1RAB9AFFAR1AKR1B1 | |
| SCHEMBL7911237 | 0.73 | PARP10 (0.64) | PARP10NPC1RAB9AFFAR1AKR1B1 | |
| SCHEMBL7222374 | 0.73 | NR4A2 (0.68) | PARP10NPC1RAB9AFFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-10-24 | — | — | US | disclosed |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | CITY OF HOPE (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE | 2017-02-23 | — | — | US | disclosed |
| EP-3035924-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | City of Hope (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015026935-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE (US) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | PTGER3 4704/4885PTGDR 4748/4885PARP10 1020/4885 |
| US-10308596-B2 | HDAC8 inhibitors for treating cancer | HDAC8, HDAC1, HDAC7 | PTGER3 4704/4885PTGDR 4748/4885PARP10 1020/4885 |
| US-20190322617-A1 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | PTGER3 4704/4885PTGDR 4748/4885PARP10 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.